-
<![CDATA[FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer]]>
12 Dec 2025 22:45 GMT
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus … phase 3 AMPLITUDE trial evaluated the now-FDA-approved treatment combination. The randomized … an androgen receptor inhibitor or docetaxel.
For more news on cancer …
-
<![CDATA[5 Key Oncology FDA Approvals From November]]>
12 Dec 2025 21:11 GMT
… FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro; Janssen Biotech … for Medical Oncology Congress.8 The trial demonstrated … docetaxel (FLOT) chemotherapy as a neoadjuvant and adjuvant treatment, … -nsclc
US FDA accepts new drug application under …
-
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
12 Dec 2025 12:00 GMT
… 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in … . This safety improvement supports better treatment exposure, an important driver of … -class therapies addressing high unmet medical needs. Its lead asset, Plinabulin …
-
<![CDATA[Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer]]>
12 Dec 2025 00:46 GMT
… -11 trial, T-DXd plus a taxane (ie, docetaxel or … drug-related ILD/pneumonitis were low across all treatment … trials.
DESTINY-Breast09 (NCT04784715) is a phase 3 trial … board certified internal medicine, hematology and medical oncologist.5
Across early …
-
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
11 Dec 2025 12:00 GMT
… meeting with the U.S. FDA. DUBLIN-4, together with DUBLIN … docetaxel as the only treatment option while multiple late-stage clinical trials have … ) and randomized, phase 3 trial in 58 medical centers (US, China, and …
-
<![CDATA[Biosimilars in 2025: A year of firsts]]>
13 Dec 2025 02:37 GMT
… combination with trastuzumab and docetaxel for adults with HER2 … November 2025 the first FDA-approved biosimilar of Tysabri … system weakened by immunosuppressant drugs. Natalizumab products are only … online at the Journal of Medical Economics in October 2025. …
-
<![CDATA[Tukysa Combo Boosts Frontline Maintenance in Advanced HER2+ Breast Cancer]]>
11 Dec 2025 16:45 GMT
… had not progressed after docetaxel with Herceptin and Perjeta, … the HER2CLIMB-05 trial?
First-line treatment for patients with … side effects,” Hamilton reported. Treatment-emergent side effects occurred … Side effects led to treatment discontinuation in 13.8% …
-
<![CDATA[How Do Experts Think Dato-DXd Should Be Used in NSCLC?]]>
10 Dec 2025 13:38 GMT
… disease subpopulations in the treatment paradigm and how best … professor of medicine and medical director of thoracic medical oncology at … the [adverse] effects. Docetaxel is very hard to tolerate … the [phase 3 FLAURA2 trial (NCT04035486) regimen of osimertinib …
-
Genomic Landscapes of 1,364 Breast Cancers
12 Dec 2025 17:46 GMT
… neoadjuvant treatment with the TCHP regimen—a potent combination of docetaxel, carboplatin … the promise of elevating clinical trial design, biomarker discovery, and … , optimizing therapeutic index and guiding drug development.
In summary, this pioneering …
-
To Explore the Mechanism of Cuproptosis in Psoriasis Based on Bioinformatics and in vivo Experiments
12 Dec 2025 16:33 GMT
… purchased from Liaoning Changsheng Biotechnology Co., Ltd. (SCXK … Imiquimod (IMQ, Tianfang Pharmaceutical Co., Ltd., Lot: … and targeted drugs such as docetaxel, doxorubicin, paclitaxel … head trials comparing different biologics in psoriasis treatment. …
About
© 1995-2025